0.00Open0.00Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover0.00%IV733.33%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier28DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma60.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Perspective Therapeutics Stock Discussion
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
$Perspective Therapeutics (CATX.US)$
1:10
$Virgin Galactic (SPCE.US)$ 1:20
$Star Equity (STRR.US)$ 1:5
$Workhorse (WKHS.US)$ 1:20
No comment yet